Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 187Neoplasm Metastasis 150Neoplasms 141Leukemia, Myeloid, Acute 138Colorectal Neoplasms 131Breast Neoplasms 120Melanoma 95Ovarian Neoplasms 93Prostatic Neoplasms 89Recurrence 85Multiple Myeloma 83Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Myelodysplastic Syndromes 66Lymphoma, Non-Hodgkin 65Triple Negative Breast Neoplasms 57Glioma 57Stomach Neoplasms 54Endometrial Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Carcinoma, Renal Cell 49Brain Neoplasms 48Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 45Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 40Advanced Solid Tumors 40

Interventions

Temozolomide 1Irinotecan 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Drug-Related Side Effects and Adverse Reactions × 90 days × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡